2026-10-30 12:56:00 UTC#545682newconfirmednews
ResMed (RMD) stock news
ResMed (RMD) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-30 00:59:42 UTC#542043newconfirmedpress release
ResMed issues FY 2027 revenue outlook of $5.75B-$5.85B and targets $1.85B+ in shareholder returns
2026-10-29 22:48:09 UTC#541581newconfirmednews
ResMed Q3 adjusted EPS $2.91 beats $2.67 estimate, revenue $1.41B beats $1.39B
2026-10-29 20:12:31 UTC#540737newconfirmednews
ResMed Q1 revenue hits $1.4B, non-GAAP EPS rises 14% to $2.91; FY27 guidance reiterated
2026-10-21 22:57:00 UTC#496457newconfirmednews
Morgan Stanley raises ResMed price target 3.6% to US$233.00 per share
2026-10-13 15:20:00 UTC#453356newforecastanalysis
Global mHealth solutions market projected to reach $275.44B by 2031, 20.4% CAGR, ResearchAndMarkets report says
yahooimportance 0.30trust 0.60Koninklijke Philips N.V. +0.20Medtronic plc +0.20Abbott Laboratories +0.20+2 entities
2026-09-15 20:07:00 UTC#316567duplicateconfirmednews
ResMed upgraded to Outperform at RBC Capital, price target raised to $262
2026-09-15 15:42:10 UTC#315125duplicateconfirmednews
ResMed (RMD) reiterates 5%-7% revenue growth guidance, cites GLP-1 and digital engagement tailwinds
2026-09-15 15:04:16 UTC#314840newconfirmednews
ResMed (RMD) issues 5%-7% revenue growth guidance, cites GLP-1 tailwinds and AI-driven patient engagement
2026-09-15 14:26:00 UTC#314575updateconfirmednews
RBC Capital Markets raises ResMed (RMD) price target to $262.00 from $244.00
2026-09-15 14:00:51 UTC#314385newconfirmednews
ResMed upgraded at RBC Capital Markets citing Q4 performance
2026-09-07 11:22:09 UTC#275992duplicateconfirmednews
ResMed FY2026 revenue $5.7B, up 8% YoY; initiates $450M accelerated share repurchase with Citibank
tradingviewimportance 0.30trust 0.70ResMed Inc. +0.50Citigroup Inc. +0.20MatrixCare +0.30+1 entities
2026-09-01 21:16:00 UTC#252014newconfirmednews
ResMed to execute $450M accelerated share repurchase agreement with Citibank
2026-08-31 12:35:00 UTC#242513newconfirmednews
KeyBanc Raises ResMed Price Target to $267.00 From $255.00
2026-08-19 14:57:00 UTC#195818newconfirmednews
Rothschild & Co initiates coverage of ResMed (RMD) at Neutral
2026-08-17 20:14:53 UTC#186449newconfirmedpress release
ResMed appoints Carol Burt as Lead Director, announces retirement of board member Ron Taylor
2026-08-13 21:25:08 UTC#174694newconfirmeddata release
ResMed Inc. FY 2026 Revenue $5.65B, Up 9.9% YoY; Diluted EPS $10.43
2026-08-13 07:20:14 UTC#170022newconfirmednews
ResMed Inc. average analyst price target lowered to $258.47, implying 14% upside
2026-08-13 04:19:00 UTC#169218newconfirmednews
ResMed CEO signals potential for further M&A in sleep disorder treatment market
dow_jonesimportance 0.40trust 0.80ResMed Inc. +0.30Noctrix Health, Inc. +0.30Mick Farrell +0.20+1 entities
2026-08-11 01:29:00 UTC#156087updateconfirmedanalysis